Ketilept (Quetiapine Fumarate)

Ketilept (quetiapine fumarate) is an atypical antipsychotic used in several psychiatric conditions.

• Schizophrenia: Reduces psychotic symptoms such as hallucinations and delusions, improving overall functioning.
• Bipolar disorder: Stabilizes mood episodes, decreasing the frequency and severity of manic and depressive phases.
• Major depressive disorder (adjunct): Enhances antidepressant response when added to standard therapy, helping patients achieve remission.

• Quetiapine fumarate acts as an antagonist at serotonin 5‑HT₂A, dopamine D₂, histamine H₁ and adrenergic α₁ receptors. By blocking 5‑HT₂A and D₂ receptors it modulates dopaminergic and serotonergic neurotransmission, reducing psychotic and mood symptoms. Additional antagonism at H₁ and α₁ contributes to its sedative and antihistaminic properties, supporting efficacy across schizophrenia, bipolar disorder and adjunctive depression treatment.

Ketilept may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Drowsiness: feeling of sleepiness or reduced alertness.
• Dry mouth: decreased salivation leading to oral discomfort.
• Constipation: slowed gastrointestinal motility causing infrequent stools.
• Weight gain: increase in body weight over time.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever, rigidity and autonomic instability.
• Tardive dyskinesia: persistent involuntary movements, especially of the face and tongue.
• Orthostatic hypotension: sudden drop in blood pressure upon standing, leading to dizziness or fainting.

When prescribing Ketilept, clinicians should consider several safety precautions to minimize risk.

• Cardiovascular monitoring: assess for orthostatic hypotension and heart rate changes, especially during initiation.
• Metabolic assessment: monitor weight, glucose and lipid levels regularly due to risk of metabolic changes.
• CNS effects: caution patients about sedation and impaired judgment; advise against operating heavy machinery until response is known.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with obstetric specialist.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ketilept interacts with several drug classes; awareness helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma concentrations, raising toxicity risk.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness by lowering drug levels.
• CNS depressants (e.g., alcohol, benzodiazepines): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

• Antihypertensives: additive effect on blood pressure lowering, monitor for hypotension.
• Anticholinergic agents: may exacerbate dry mouth and constipation, adjust therapy as needed.
• QT‑prolonging drugs: combined use may increase risk of cardiac arrhythmias; ECG monitoring recommended.